FR2413974B1 - - Google Patents

Info

Publication number
FR2413974B1
FR2413974B1 FR7800305A FR7800305A FR2413974B1 FR 2413974 B1 FR2413974 B1 FR 2413974B1 FR 7800305 A FR7800305 A FR 7800305A FR 7800305 A FR7800305 A FR 7800305A FR 2413974 B1 FR2413974 B1 FR 2413974B1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR7800305A
Other languages
French (fr)
Other versions
FR2413974A1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9203176&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR2413974(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Priority to FR7800305A priority Critical patent/FR2413974A1/fr
Priority to EP19780400265 priority patent/EP0003089B1/fr
Priority to DE7878400265T priority patent/DE2860970D1/de
Publication of FR2413974A1 publication Critical patent/FR2413974A1/fr
Application granted granted Critical
Publication of FR2413974B1 publication Critical patent/FR2413974B1/fr
Granted legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
    • B41F—PRINTING MACHINES OR PRESSES
    • B41F23/00—Devices for treating the surfaces of sheets, webs, or other articles in connection with printing
    • B41F23/04—Devices for treating the surfaces of sheets, webs, or other articles in connection with printing by heat drying, by cooling, by applying powders
    • B41F23/044—Drying sheets, e.g. between two printing stations
    • B41F23/0443—Drying sheets, e.g. between two printing stations after printing
    • B41F23/0446—Wicket conveyors
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F26—DRYING
    • F26B—DRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM
    • F26B15/00—Machines or apparatus for drying objects with progressive movement; Machines or apparatus with progressive movement for drying batches of material in compact form
    • F26B15/02—Machines or apparatus for drying objects with progressive movement; Machines or apparatus with progressive movement for drying batches of material in compact form with movement in the whole or part of a circle
    • F26B15/08—Machines or apparatus for drying objects with progressive movement; Machines or apparatus with progressive movement for drying batches of material in compact form with movement in the whole or part of a circle in a vertical plane
    • F26B15/085—Machines or apparatus for drying objects with progressive movement; Machines or apparatus with progressive movement for drying batches of material in compact form with movement in the whole or part of a circle in a vertical plane with endless clamp or tray conveyor, e.g. wicket conveyor

Landscapes

  • Engineering & Computer Science (AREA)
  • Mechanical Engineering (AREA)
  • General Engineering & Computer Science (AREA)
  • Drying Of Solid Materials (AREA)
  • Supply, Installation And Extraction Of Printed Sheets Or Plates (AREA)
FR7800305A 1978-01-06 1978-01-06 Sechoir pour feuilles imprimees par serigraphie Granted FR2413974A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
FR7800305A FR2413974A1 (fr) 1978-01-06 1978-01-06 Sechoir pour feuilles imprimees par serigraphie
EP19780400265 EP0003089B1 (fr) 1978-01-06 1978-12-27 Séchoir pour feuilles imprimées par sérigraphie
DE7878400265T DE2860970D1 (en) 1978-01-06 1978-12-27 Drier for silkscreen printed sheets

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7800305A FR2413974A1 (fr) 1978-01-06 1978-01-06 Sechoir pour feuilles imprimees par serigraphie

Publications (2)

Publication Number Publication Date
FR2413974A1 FR2413974A1 (fr) 1979-08-03
FR2413974B1 true FR2413974B1 (enExample) 1982-12-03

Family

ID=9203176

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7800305A Granted FR2413974A1 (fr) 1978-01-06 1978-01-06 Sechoir pour feuilles imprimees par serigraphie

Country Status (3)

Country Link
EP (1) EP0003089B1 (enExample)
DE (1) DE2860970D1 (enExample)
FR (1) FR2413974A1 (enExample)

Families Citing this family (453)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5708142A (en) 1994-05-27 1998-01-13 Genentech, Inc. Tumor necrosis factor receptor-associated factors
US20050089958A1 (en) * 1996-01-09 2005-04-28 Genentech, Inc. Apo-2 ligand
US6030945A (en) * 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
US6998116B1 (en) 1996-01-09 2006-02-14 Genentech, Inc. Apo-2 ligand
CA2249206A1 (en) 1996-04-01 1997-10-09 Genentech, Inc. Apo-2li and apo-3 apoptosis polypeptides
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
US6159462A (en) * 1996-08-16 2000-12-12 Genentech, Inc. Uses of Wnt polypeptides
US6462176B1 (en) 1996-09-23 2002-10-08 Genentech, Inc. Apo-3 polypeptide
US5990281A (en) * 1996-09-30 1999-11-23 Genentech, Inc. Vertebrate smoothened proteins
US6136958A (en) * 1996-09-30 2000-10-24 Genentech, Inc. Antibodies to vertebrate smoothened proteins
DK0942992T3 (da) 1997-01-31 2007-07-02 Genentech Inc O-fucosyltransferase
US6121428A (en) 1997-06-13 2000-09-19 Genentech, Inc. Protein recovery
WO1999014330A1 (en) 1997-09-18 1999-03-25 Genentech, Inc. DcR3 POLYPEPTIDE, A TNFR HOMOLOG
AU749948B2 (en) 1997-10-10 2002-07-04 Genentech Inc. APO-3 ligand
EP2033970A3 (en) 1997-10-29 2009-06-17 Genentech, Inc. Polypeptides and nucleic acids encoding the same
US7192589B2 (en) 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
DK1481990T3 (da) 1997-11-21 2007-10-01 Genentech Inc A33-beslægtede antigener og deres farmakologiske anvendelser
NZ522634A (en) 1997-12-03 2004-02-27 Genentech Inc PRO243 encoding a polypeptide with homology to chordin and antibodies and vectors
EP1947119A3 (en) 1997-12-12 2012-12-19 Genentech, Inc. Treatment of cancer with anti-erb2 antibodies in combination with a chemotherapeutic agent
CA2318029C (en) 1998-01-15 2009-05-19 Genentech, Inc. Apo-2 ligand
ES2292242T5 (es) 1998-05-15 2011-05-04 Genentech, Inc. Utilizaciones terapéuticas de polipéptidos homólogos de il-17.
SI1135498T1 (sl) 1998-11-18 2008-06-30 Genentech Inc Variante protitelesa z višjo vezavno afiniteto vprimerjavi z izvirnimi protitelesi
CA2450402A1 (en) 1998-12-22 2000-06-29 Genentech, Inc. Methods and compositions for inhibiting cancer cell growth comprising pro224
CA2354027A1 (en) 1998-12-23 2000-07-06 Genentech, Inc. Il-1 related polypeptides
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
DE60043367D1 (de) 1999-06-15 2009-12-31 Genentech Inc Sekretierte und Transmembran-Polypeptide sowie Nukleinsäuren zu deren Kodierung
AR024464A1 (es) 1999-06-25 2002-10-02 Genentech Inc Anticuerpos anti-erbb2 humanizados.
EP2110138A1 (en) 1999-08-27 2009-10-21 Genentech, Inc. Dosages for treatment of anti-erbB2 antibodies
CA2391455A1 (en) 1999-12-01 2001-06-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
DK1897944T3 (da) 1999-12-23 2011-10-24 Genentech Inc IL-17 homologe polypeptider og terapeutisk anvendelse deraf
CN1425066B (zh) 2000-01-13 2010-05-26 杰南技术公司 新的stra6多肽
US6740520B2 (en) 2000-03-21 2004-05-25 Genentech, Inc. Cytokine receptor and nucleic acids encoding the same
EP2075253A1 (en) 2000-06-23 2009-07-01 Genentech, Inc. Compositions and methds for the diagnosis and treatment of disorders involving angiogensis
EP2792747A1 (en) 2000-06-23 2014-10-22 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
WO2002009755A2 (en) 2000-07-27 2002-02-07 Genentech, Inc. Apo-2l receptor agonist and cpt-11 synergism
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
DE60136281D1 (de) 2000-08-24 2008-12-04 Genentech Inc Methode zur inhibierung von il-22 induziertem pap1
EP1944317A3 (en) 2000-09-01 2008-09-17 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
DE60139944D1 (de) 2000-10-12 2009-10-29 Genentech Inc Niederviskose konzentrierte proteinformulierungen
US20020159996A1 (en) 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
KR20100132559A (ko) 2001-05-30 2010-12-17 제넨테크, 인크. 다양한 질환의 치료에 유용한 항-엔지에프 항체
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
EP1409549A4 (en) 2001-06-20 2007-10-24 Genentech Inc COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMORS
KR100942880B1 (ko) 2001-08-29 2010-02-17 제넨테크, 인크. 유사분열촉진 활성을 가진 Ｂｖ８ 핵산 및 폴리펩티드
NZ573739A (en) 2001-09-18 2010-07-30 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor, particularly colorectal tumor - TAT201
BRPI0214168B8 (pt) 2001-11-14 2021-05-25 Centocor Inc anticorpos anti-il-6, moléculas de ácido nucleico codificando os mesmos, vetores compreendendo as referidas moléculas, composições e formulações compreendendo os referidos anticorpos, bem como métodos de produção dos mesmos
AU2002362197A1 (en) 2001-12-28 2003-07-24 Chugai Seiyaku Kabushiki Kaisha Method of stabilizing protein
EP1575571A4 (en) 2002-01-02 2008-06-25 Genentech Inc COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF A TUMOR
US7452675B2 (en) 2002-01-25 2008-11-18 The Queen's Medical Center Methods of screening for TRPM4b modulators
US20040258678A1 (en) 2002-02-22 2004-12-23 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US7303896B2 (en) 2002-02-25 2007-12-04 Genentech, Inc. Nucleic acid encoding novel type-1 cytokine receptor GLM-R
EP2305710A3 (en) 2002-06-03 2013-05-29 Genentech, Inc. Synthetic antibody phage libraries
HUP0600340A3 (en) 2002-07-15 2011-06-28 Genentech Inc Methods for identifying tumors that are responsive to treatment with anti-erbb2 antibodies
PT1543038T (pt) 2002-09-11 2017-07-07 Genentech Inc Purificação de proteína
JP2006521082A (ja) 2002-09-11 2006-09-21 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための新規組成物と方法
AU2003291625B2 (en) 2002-09-16 2009-10-08 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2004028479A2 (en) 2002-09-25 2004-04-08 Genentech, Inc. Nouvelles compositions et methodes de traitement du psoriasis
AU2003298607B9 (en) 2002-10-29 2011-08-04 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
AU2003295401B2 (en) 2002-11-08 2010-04-29 Genentech, Inc. Compositions and methods for the treatment of natural killer cell related diseases
EP1572116A4 (en) 2002-11-26 2007-12-12 Genentech Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES
DK1575517T3 (da) 2002-12-24 2012-05-14 Rinat Neuroscience Corp Anti-ngf-antistoffer og fremgangsmåder til anvendelse af samme
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
CN102225194B (zh) 2003-03-12 2014-07-16 健泰科生物技术公司 Bv8和/或EG-VEGF促进造血的用途
CA2519241A1 (en) 2003-04-01 2004-11-11 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
RS20150135A1 (sr) 2003-05-30 2015-08-31 Genentech Inc. Tretman sa anti-vegf antitelima
ES2537738T3 (es) 2003-06-05 2015-06-11 Genentech, Inc. Terapia de combinación para trastornos de células B
KR20060015646A (ko) 2003-06-13 2006-02-17 유니버시티 오브 피츠버그 면역, 혈액 및 염증성 질환의 모니터링 방법
DK1641822T3 (da) 2003-07-08 2013-07-22 Genentech Inc Heterologe il-17-a/f-polypeptider og terapeutiske anvendelser deraf.
JP4599355B2 (ja) 2003-07-28 2010-12-15 ジェネンテック， インコーポレイテッド プロテインａアフィニティークロマトグラフィーの間のプロテインａの浸出の低減
ATE528397T1 (de) 2003-08-08 2011-10-15 Perseus Proteomics Inc Bei krebs überexprimiertes gen
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
NZ576411A (en) 2003-11-17 2010-04-30 Genentech Inc Compositions and methods for the treatment of tumor of hematopoietic origin
CN1914226B (zh) 2003-11-25 2012-02-01 达纳-法伯癌症研究院有限公司 SARS-CoV抗体及其使用方法
US7312320B2 (en) 2003-12-10 2007-12-25 Novimmune Sa Neutralizing antibodies and methods of use thereof
CN1922208A (zh) 2003-12-11 2007-02-28 健泰科生物技术公司 用于抑制c－met二聚化及活化的方法和组合物
JP4503617B2 (ja) 2003-12-23 2010-07-14 ライナット ニューロサイエンス コーポレイション アゴニスト抗ｔｒｋＣ抗体および該抗体を用いる方法
EP2168986A3 (en) 2004-02-19 2010-07-28 Genentech, Inc. CDR-repaired antibodies
SG183012A1 (en) 2004-06-04 2012-08-30 Genentech Inc Method for treating multiple sclerosis
SI1771474T1 (sl) 2004-07-20 2010-06-30 Genentech Inc Inhibitorji angiopoetinu podobnega proteina kombinacije in njihova uporaba
AU2005290250A1 (en) 2004-07-30 2006-04-06 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
DK1841793T3 (da) 2005-01-07 2010-07-19 Diadexus Inc Ovr110-antistofsammensætninger og fremgangsmåder til anvendelse deraf
EP3698807A1 (en) 2005-01-21 2020-08-26 Genentech, Inc. Fixed dosing of her antibodies
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
PT1853718E (pt) 2005-02-15 2015-11-12 Univ Duke Anticorpos anti-cd19 e usos em oncologia
US20060263357A1 (en) 2005-05-05 2006-11-23 Tedder Thomas F Anti-CD19 antibody therapy for autoimmune disease
RS53128B (sr) 2005-02-23 2014-06-30 Genentech Inc. Produžavanje vremena progresije bolesti ili preživljavanja kod pacijenata obolelih od kancera jajnika korišćenjem pertuzumaba
US8278069B2 (en) 2005-04-11 2012-10-02 National Research Council Of Canada Identification of a β-1,3-N-acetylgalactosaminyltransferase (CGTE) from Campylobacter jejuni LIO87
PA8672101A1 (es) 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
US20080248039A1 (en) 2005-04-29 2008-10-09 The Regents Of The University Of California Antibodies Against Histone Modifications for Clinical Diagnosis and Prognosis of Cancer
WO2007001677A2 (en) 2005-05-17 2007-01-04 University Of Connecticut Compositions and methods for immunomodulation in an organism
CA2613818C (en) 2005-06-30 2013-08-27 Centocor, Inc. Anti-il-23 antibodies, compositions, methods and uses
DK2573114T3 (en) 2005-08-10 2016-07-04 Macrogenics Inc The identification and production of antibodies with variant Fc regions, and methods of using same
SI3045182T1 (en) 2005-11-14 2018-08-31 Teva Pharmaceuticals International Gmbh An antibody to a peptide-associated peptide antagonist to calcitonin for treating a headache in aggregates
EP1979379B1 (en) 2005-12-02 2013-09-18 Dana-Farber Cancer Institute Carbonic anhydrase ix (g250) antibodies and methods of use thereof
JP2009518314A (ja) 2005-12-02 2009-05-07 ジェネンテック・インコーポレーテッド Ｉｌ−２２に結合する抗体およびｉｌ−２２ｒに結合する抗体を含む、サイトカインシグナリングに関連する疾患および障害の処置のための組成物および方法
EP1973948B1 (en) 2005-12-15 2015-02-11 Genentech, Inc. Methods and compositions for targeting polyubiquitin
SI3219328T1 (sl) 2005-12-29 2020-10-30 Janssen Biotech, Inc. Človeška protitelesa proti-IL-23, sestavki, postopki in uporabe
US8101365B2 (en) 2006-01-05 2012-01-24 Genentech, Inc. Anti-EphB4 antibodies and methods using same
ATE491948T1 (de) 2006-02-06 2011-01-15 Rhode Island Hospital Gpr30-östrogenrezeptor bei mammakarzinomen
CA2638821A1 (en) 2006-02-17 2007-10-11 Genentech, Inc. Gene disruptons, compositions and methods relating thereto
EP2650306A1 (en) 2006-03-06 2013-10-16 Aeres Biomedical Limited Humanized Anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
EP2004230A4 (en) 2006-03-21 2009-05-20 Univ California N-CADHERINE AND LY6 E: OBJECTIVES FOR CANCER DIAGNOSIS AND THERAPY
US20100278821A1 (en) 2006-03-21 2010-11-04 The Regents Of The University Of California N-cadherin: target for cancer diagnosis and therapy
AR060040A1 (es) 2006-03-21 2008-05-21 Genentech Inc Antagonistas de vefg y de alfa5 beta 1
EP2004221A2 (en) 2006-03-23 2008-12-24 Novartis Pharma AG Anti-tumor cell antigen antibody therapeutics
CA2647277A1 (en) 2006-04-05 2007-11-08 Genentech, Inc. Method for using boc/cdo to modulate hedgehog signaling
WO2007131133A2 (en) 2006-05-04 2007-11-15 Genentech, Inc. Methods and compositions relating to zpa polypeptides
PT2032606E (pt) 2006-05-30 2014-02-05 Genentech Inc Anticorpos e imunoconjugados e respetivas utilizações
EP2024391A2 (en) 2006-06-01 2009-02-18 Genentech, Inc. Crystal structure of crig and c3b: crig complex
BRPI0712850A8 (pt) 2006-06-07 2018-05-02 Bioalliance Cv anticorpos que reconhecem um epitopo contendo carboidrato em cd-43 e cea expressados em células cancerígenas e métodos de uso dos mesmos
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
WO2008054561A2 (en) 2006-07-11 2008-05-08 University Of Medicine And Dentistry Of New Jersey Proteins, nucleic acids encoding the same and associated methods of use
DK2046809T3 (en) 2006-07-19 2017-03-13 Univ Pennsylvania WSX-1 / IL-27 AS A TARGET OBJECTIVE FOR ANTI-INFLAMMATORY REACTIONS
CA2660286A1 (en) 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use
ZA200900954B (en) 2006-08-22 2010-05-26 G2 Inflammation Pty Ltd Ant-C5aR antibodies with improved properties
EP2061900A2 (en) 2006-08-25 2009-05-27 Oncotherapy Science, Inc. Prognostic markers and therapeutic targets for lung cancer
CN105061580B (zh) 2006-10-03 2020-06-05 罗格斯新泽西州立大学 多肽和药物组合物及其应用
PT2845866T (pt) 2006-10-27 2017-08-09 Genentech Inc Anticorpos e imunoconjugados e utilizações dos mesmos
WO2008140586A2 (en) 2006-11-21 2008-11-20 The Regents Of The University Of California Modulation of rhamm (cd168) for selective adipose tissue development
AU2007325283B2 (en) 2006-11-27 2012-08-30 Diadexus, Inc. Ovr110 antibody compositions and methods of use
RU2502806C2 (ru) 2007-02-22 2013-12-27 Дженентек, Инк. Способы выявления воспалительного заболевания кишечника
MX2009008981A (es) 2007-03-02 2009-09-02 Genentech Inc Prediccion de respuesta a un inhibidor her.
BRPI0811466A2 (pt) 2007-05-07 2014-10-14 Medimmune Llc Anticorpo anti-icos isolado, ácido nucleico, vetor, célula isolada, métodos para produzir um anticorpo, para tratar uma doença ou distúrbio, para tratar ou prevenir a rejeição em um paciente de transplante humano, para tratar uma malignidade de célula t em um ser humano, para esgotar células t que expressam icos em um paciente humano, para romper a arquitetura do centro germinal em um órgão linfóide secundário de um primata, para esgotar células b centrais germinais de órgão linfóide secundário de um primata, e para esgotar células b comutadas em classes circulantes em um primata, e, composição farmacêutica.
SI2173381T1 (sl) 2007-05-14 2014-01-31 Novimmune Sa Fc receptor-vezavni polipeptidi z modificiranimi efektorskimi funkcijami
WO2008154249A2 (en) 2007-06-08 2008-12-18 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
MX2009012924A (es) 2007-06-08 2010-03-25 Australian Poultry Crc Pty Ltd Toxina clostridial netb.
EP2586788B1 (en) 2007-07-09 2017-11-29 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
PE20140625A1 (es) 2007-07-16 2014-05-29 Genentech Inc ANTICUERPOS ANTI-CD79b E INMUNOCONJUGADOS HUMANIZADOS
PT2474557E (pt) 2007-07-16 2014-12-03 Genentech Inc Anticorpos e imunoconjugados anti-cd79b e métodos de utilização
EP2185719B1 (en) 2007-08-02 2013-11-13 NovImmune SA Anti-rantes antibodies and methods of use thereof
AU2008308761B2 (en) 2007-10-02 2014-10-16 Genentech, Inc. NLRR-1 antagonists and uses thereof
US20090202475A1 (en) 2007-11-07 2009-08-13 Genentech, Inc. Compositions and methods for treatment of microbial disorders
AU2008334095A1 (en) 2007-11-29 2009-06-11 Genentech, Inc. Gene expression markers for inflammatory bowel disease
US8420081B2 (en) 2007-11-30 2013-04-16 Abbvie, Inc. Antibody formulations and methods of making same
TWI468417B (zh) 2007-11-30 2015-01-11 Genentech Inc 抗－ｖｅｇｆ抗體
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
EP3524619A1 (en) 2007-12-06 2019-08-14 Dana-Farber Cancer Institute, Inc. Antibodies against influenza virus and methods of use thereof
JP5737944B2 (ja) 2007-12-17 2015-06-17 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 間質性膀胱炎の治療
CN105732813A (zh) 2007-12-18 2016-07-06 生物联合公司 识别癌细胞上表达的cd-43和cea的含糖表位的抗体及其使用方法
CA2711370C (en) 2008-01-15 2017-06-13 The Board Of Trustees Of The Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
DK2657253T3 (en) 2008-01-31 2017-10-09 Genentech Inc Anti-CD79b antibodies and immune conjugates and methods of use
WO2009126688A2 (en) 2008-04-09 2009-10-15 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
WO2009140684A2 (en) 2008-05-16 2009-11-19 Genentech, Inc. Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7integrin antagonists
WO2009147695A1 (ja) 2008-06-02 2009-12-10 国立大学法人東京大学 抗がん剤
WO2009151514A1 (en) 2008-06-11 2009-12-17 Millipore Corporation Stirred tank bioreactor
WO2009150623A1 (en) 2008-06-13 2009-12-17 Pfizer Inc Treatment of chronic prostatitis
US20120128684A1 (en) 2008-08-25 2012-05-24 Burnham Institute For Medical Research Conserved Hemagglutinin Epitope, Antibodies to the Epitope and Methods of Use
US8790642B2 (en) 2008-08-29 2014-07-29 Genentech, Inc. Cross-reactive and bispecific anti-IL-17A/F antibodies
AU2009291747B2 (en) 2008-09-10 2016-05-26 Genentech, Inc. Methods for inhibiting ocular angiogenesis
TWI445716B (zh) 2008-09-12 2014-07-21 Rinat Neuroscience Corp Ｐｃｓｋ９拮抗劑類
AR073295A1 (es) 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
CN102264763B (zh) 2008-09-19 2016-04-27 米迪缪尼有限公司 定向于dll4的抗体及其用途
AU2009303526B2 (en) 2008-10-14 2015-01-15 Genentech, Inc. Immunoglobulin variants and uses thereof
WO2010056804A1 (en) 2008-11-12 2010-05-20 Medimmune, Llc Antibody formulation
US20110020327A1 (en) 2008-12-16 2011-01-27 Millipore Corporation Purification of proteins
JP2012512261A (ja) 2008-12-17 2012-05-31 ジェネンテック， インコーポレイテッド Ｃ型肝炎ウイルス併用療法
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
MX2011006870A (es) 2008-12-23 2011-07-19 Genentech Inc Variantes de inmunoglobulina con union alterada a proteina a.
EP2379595A2 (en) 2008-12-23 2011-10-26 AstraZeneca AB Targeted binding agents directed to 5 1 and uses thereof
WO2010086828A2 (en) 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Agonist anti-trkb monoclonal antibodies
SI3260136T1 (sl) 2009-03-17 2021-05-31 Theraclone Sciences, Inc. Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
ES2549769T3 (es) 2009-03-25 2015-11-02 Genentech, Inc. Anticuerpos anti-FGFR3 y métodos que emplean los mismos
MA33256B1 (fr) 2009-04-01 2012-05-02 Genentech Inc Anticorps et immunoconjugués anti-fcrh5 et procédés d'utilisation
EP2427203B1 (en) 2009-05-05 2018-10-17 Novimmune S.A. Anti-il-17f antibodies and use thereof
WO2010146511A1 (en) 2009-06-17 2010-12-23 Pfizer Limited Treatment of overactive bladder
EP2451843A1 (en) 2009-07-07 2012-05-16 F. Hoffmann-La Roche AG Diagnosis and treatment of autoimmune demyelinating diseases
US20110033486A1 (en) 2009-07-20 2011-02-10 Abbas Alexander R Gene expression markers for crohn's disease
TW201106972A (en) 2009-07-27 2011-03-01 Genentech Inc Combination treatments
EP4786482A2 (en) 2009-08-06 2026-08-05 F. Hoffmann-La Roche AG Virus filtration methods
WO2011019620A1 (en) 2009-08-10 2011-02-17 Genentech, Inc. Antibodies with enhanced adcc function
US20110038871A1 (en) 2009-08-11 2011-02-17 Veena Viswanth Ccr2 inhibitors for treating conditions of the eye
MX355650B (es) 2009-08-11 2018-04-26 Genentech Inc Produccion de proteinas en medios de cultivo de celulas libres de glutamina.
US20110053223A1 (en) 2009-08-14 2011-03-03 Robert Bayer Cell culture methods to make antibodies with enhanced adcc function
BR112012004697B8 (pt) 2009-09-01 2021-05-25 Genentech Inc método para purificar um polipeptídeo compreendendo uma região ch2/ch3
JP5887270B2 (ja) 2009-09-02 2016-03-16 ジェネンテック， インコーポレイテッド 突然変異体ｓｍｏｏｔｈｅｎｅｄおよびその使用方法
MX2012004029A (es) 2009-10-07 2012-05-08 Macrogenics Inc Polipeptidos que contienen la region fc que exhiben funcion efectora mejorada debido a alteraciones del grado de fucosilacion, y metodos para su uso.
EP2488640B1 (en) 2009-10-14 2018-09-26 Nanyang Technological University Antiproliferative agent
RU2539772C2 (ru) 2009-10-22 2015-01-27 Дженентек, Инк. Способы и композиции для модуляции гепсином стимулирующего макрофаги белка
EP2491059B1 (en) 2009-10-22 2015-02-25 F.Hoffmann-La Roche Ag Anti-hepsin antibodies and methods using same
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
KR101968766B1 (ko) 2009-11-05 2019-04-12 제넨테크, 인크. 이종 폴리펩티드의 분비를 위한 방법 및 조성물
BR112012009997A2 (pt) 2009-11-12 2019-09-24 Genentech Inc ''método para aumentar a densidade de espinhas dentriticas nos neurônios de um paciente com um distúrbios cognitivo ou psiquiatrico,método de manutenção da cognição em um sujeito durante o processo de envelhecimento,uso de um antagonista de dr6 na preparação de um medicamento para uso em um paciente com um disturbio cognitivo uo psiquíatrico e uso de um antagonista de p75 na preparação de um medicamento para uso em um paciente com um distúrbio cognitivo ou psiquiátrico''
EP2501409A4 (en) 2009-11-20 2015-02-18 Univ California EPITHELIAL MEMBRANE PROTEIN-2 (EMP2) AND PROLIFERATIVE VITREORETINOPATHY (PVR)
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
TWI507524B (zh) 2009-11-30 2015-11-11 建南德克公司 診斷及治療腫瘤之組合物及方法
US8486397B2 (en) 2009-12-11 2013-07-16 Genentech, Inc. Anti-VEGF-C antibodies and methods using same
CN107095846A (zh) 2009-12-21 2017-08-29 霍夫曼-拉罗奇有限公司 抗体配制剂
MX2012007379A (es) 2009-12-23 2012-08-31 Genentech Inc Anticuerpos anti-bv8 y usos de los mismos.
CN102781964B (zh) 2009-12-28 2015-11-25 肿瘤疗法科学股份有限公司 抗cdh3抗体及其用途
US20110159588A1 (en) 2009-12-30 2011-06-30 Kui Lin Methods for Modulating a PDGF-AA Mediated Biological Response
WO2011094759A2 (en) 2010-02-01 2011-08-04 The Regents Of The University Of California Novel diagnostic and therapeutic targets associated with or regulated by n-cadherin expression and/or epithelial to mesenchymal transition (emt) in prostate cancer and other malignancies
AR080154A1 (es) 2010-02-10 2012-03-14 Immunogen Inc Anticuerpos cd20 y su utilizacion
WO2011103490A2 (en) 2010-02-18 2011-08-25 The Regents Of The University Of California INTEGRIN αVβ8 NEUTRALIZING ANTIBODY
AU2011221226A1 (en) 2010-02-23 2012-08-16 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AR080291A1 (es) 2010-02-24 2012-03-28 Rinat Neuroscience Corp Anticuerpos antagonistas anti receptor de il-7 y procedimientos
NZ602220A (en) 2010-03-11 2014-10-31 Rinat Neuroscience Corp Antibodies with ph dependent antigen binding
PL2552961T3 (pl) 2010-03-30 2018-04-30 Janssen Biotech, Inc. Humanizowane przeciwciała il-25
CN102958941A (zh) 2010-05-03 2013-03-06 霍夫曼-拉罗奇有限公司 用于肿瘤诊断和治疗的组合物和方法
BR112012027828A2 (pt) 2010-05-03 2016-08-09 Genentech Inc composição de matéria, artigo de fabricação e método de redução da viscosidade de uma formulação contendo proteína e de preparação de uma formulação aquosa contendo proteína
CN102892791B (zh) 2010-05-17 2017-05-17 Emd密理博公司 用于纯化生物分子的刺激响应性聚合物
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
HRP20171095T4 (hr) 2010-05-25 2022-07-22 F. Hoffmann - La Roche Ag Postupci pročišćavanja polipeptida
JP6050226B2 (ja) 2010-05-28 2016-12-21 ジェネンテック， インコーポレイテッド Ｌｄｈ及びｐｄｈｋ発現を下方制御することによる乳酸レベルの低下及びポリペプチド生産の増加
EP3957653A1 (en) 2010-06-02 2022-02-23 Dana Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
NZ701208A (en) 2010-06-03 2016-05-27 Genentech Inc Immuno-pet imaging of antibodies and immunoconjugates and uses thereof
US20110311527A1 (en) 2010-06-16 2011-12-22 Allergan, Inc. IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS
NZ603581A (en) 2010-06-19 2015-05-29 Sloan Kettering Inst Cancer Anti-gd2 antibodies
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
CN104474546A (zh) 2010-08-13 2015-04-01 弗·哈夫曼-拉罗切有限公司 用于疾病治疗的针对IL-1β和IL-18的抗体
SG10201506782XA (en) 2010-08-27 2015-10-29 Stem Centrx Inc Notum protein modulators and methods of use
CA3201524C (en) 2010-08-31 2026-01-13 International Aids Vaccine Initiative Human immunodeficiency virus (hiv)-neutralizing antibodies
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
CN106620693A (zh) 2010-09-03 2017-05-10 艾伯维施特姆森特克斯有限责任公司 新型调节剂及使用方法
US8481680B2 (en) 2010-10-05 2013-07-09 Genentech, Inc. Mutant smoothened and methods of using the same
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
EP2640831A1 (en) 2010-11-17 2013-09-25 Sea Lane Biotechnologies,llc. Influenza virus neutralizing agents that mimic the binding site of an influenza neutralizing antibody
WO2012071436A1 (en) 2010-11-24 2012-05-31 Genentech, Inc. Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants
PH12013501137A1 (en) 2010-12-08 2021-06-02 Abbvie Stemcentrx Llc Novel modulators and methods of use
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
AU2012229188A1 (en) 2011-03-15 2013-09-26 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
MX2013011130A (es) 2011-03-31 2013-10-30 Genentech Inc Metodos de administracion de antagonistas de integrina beta7.
JP5908972B2 (ja) 2011-04-07 2016-04-26 アムジエン・インコーポレーテツド 新規な抗原結合タンパク質
DK2714738T3 (en) 2011-05-24 2019-01-28 Zyngenia Inc MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
WO2013012855A1 (en) 2011-07-18 2013-01-24 Amgen Inc. Apelin antigen-binding proteins and uses thereof
KR20140091721A (ko) 2011-11-02 2014-07-22 제넨테크, 인크. 오버로드 및 용리 크로마토그래피
US9574010B2 (en) 2011-11-04 2017-02-21 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the Fc domain
SG11201401699WA (en) 2011-11-11 2014-09-26 Rinat Neuroscience Corp Antibodies specific for trop-2 and their uses
WO2013093693A1 (en) 2011-12-22 2013-06-27 Rinat Neuroscience Corp. Staphylococcus aureus specific antibodies and uses thereof
RU2014123030A (ru) 2011-12-22 2016-02-20 Ринат Ньюросайенс Корп. Антагонистические антитела против человеческого рецептора гормона роста и способы их применения
WO2013096812A1 (en) 2011-12-23 2013-06-27 Genentech, Inc. Articles of manufacture and methods for co-administration of antibodies
WO2013101771A2 (en) 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
US20140050720A1 (en) 2012-01-09 2014-02-20 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
EP2802601B1 (en) 2012-01-09 2019-11-13 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
ME03512B (me) 2012-02-06 2020-04-20 Inhibrx Inc Cd47 antitijela i postupci za njihovu upotrebu
CN104520324A (zh) 2012-02-24 2015-04-15 施特姆森特Rx股份有限公司 Dll3调节剂及其使用方法
HUE037613T2 (hu) 2012-03-29 2018-09-28 Novimmune Sa Anti-TLR4 antitestek és azok felhasználása
AU2013256010B2 (en) 2012-05-04 2018-01-04 Dana-Farber Cancer Institute, Inc. Affinity matured anti-CCR4 humanized monoclonal antibodies and methods of use
JP6351572B2 (ja) 2012-05-10 2018-07-04 ザイムワークス，インコーポレイテッド Ｆｃドメインに突然変異を有する免疫グロブリン重鎖のヘテロ多量体構築物
JP2015525230A (ja) 2012-06-11 2015-09-03 アムジエン・インコーポレーテツド デュアル受容体アンタゴニスト性抗原結合タンパク質およびその使用
ES2817897T3 (es) 2012-07-23 2021-04-08 La Jolla Inst Allergy & Immunology PTPRS y proteoglicanos en enfermedad autoinmune
US20150239991A1 (en) 2012-09-25 2015-08-27 Glenmark Pharmaceuticals S.A. Purification of hetero-dimeric immunoglobulins
BR112015007672A2 (pt) 2012-10-04 2017-08-08 Dana Farber Cancer Inst Inc anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
KR101850591B1 (ko) 2012-10-05 2018-04-19 제넨테크, 인크. 염증성 장 질환의 진단 및 치료 방법
RU2015115956A (ru) 2012-11-09 2017-01-10 Пфайзер Инк. Антитела, специфичные в отношении фактора роста тромбоцитов в, и их композиции и применения
RU2693078C2 (ru) 2012-12-03 2019-07-01 Новиммун С.А. Анти-cd47 антитела и способы их применения
SG10201706383XA (en) 2013-02-06 2017-09-28 Inhibrx Lp Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
ES2731681T3 (es) 2013-02-22 2019-11-18 Abbvie Stemcentrx Llc Conjugados de anticuerpo anti-DLL3 y PBD y usos de los mismos
HK1212613A1 (zh) 2013-03-13 2016-06-17 豪夫迈‧罗氏有限公司 具有降低的氧化的配制物
SG11201507043SA (en) 2013-03-13 2015-10-29 Genentech Inc Formulations with reduced oxidation
MX365567B (es) 2013-03-13 2019-06-07 Genentech Inc Formulaciones de anticuerpo.
SG10201809452RA (en) 2013-03-15 2018-11-29 Genentech Inc Cell culture compositions with antioxidants and methods for polypeptide production
AU2014228772B2 (en) 2013-03-15 2019-02-28 Memorial Sloan Kettering Cancer Center High affinity anti-GD2 antibodies
MX2015013163A (es) 2013-03-15 2016-04-04 Zyngenia Inc Complejos multiespecificos multivalente y monovalentes y sus usos.
EP4292657A3 (en) 2013-03-15 2024-03-20 Dana Farber Cancer Institute, Inc. Flavivirus neutralizing antibodies and methods of use thereof
US9447193B2 (en) 2013-03-24 2016-09-20 Development Center For Biotechnology Methods for suppressing cancer by inhibition of TMCC3
JP6615745B2 (ja) 2013-03-27 2019-12-04 ジェネンテック， インコーポレイテッド ベータ７インテグリンアンタゴニストによる胃腸炎症障害の治療を評価するためのバイオマーカーの使用
JP2016518126A (ja) 2013-04-19 2016-06-23 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ローンスターウイルス
CN105189560A (zh) 2013-05-07 2015-12-23 瑞纳神经科学公司 抗胰高血糖素受体抗体和其使用方法
KR102251127B1 (ko) 2013-07-12 2021-05-11 제넨테크, 인크. 이온 교환 크로마토그래피 입력 최적화의 설명
TWI888366B (zh) 2013-07-16 2025-07-01 美商建南德克公司 利用pd-1軸結合拮抗劑及tigit抑制劑治療癌症之方法
JP6687520B2 (ja) 2013-07-18 2020-04-22 トーラス バイオサイエンシズ リミテッド ライアビリティ カンパニー 極めて長い相補性決定領域を有するヒト化抗体
WO2015017146A2 (en) 2013-07-18 2015-02-05 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
MX2016001854A (es) 2013-08-12 2016-09-06 Genentech Inc Composiciones y metodo para tratar condiciones asociadas con el complemento.
AU2014306564B2 (en) 2013-08-14 2019-10-17 Antlera Therapeutics Inc. Antibodies against frizzled proteins and methods of use thereof
JP2016531915A (ja) 2013-08-28 2016-10-13 ステムセントリックス， インコーポレイテッド 部位特異的抗体コンジュゲーション方法および組成物
CA2922529A1 (en) 2013-08-28 2015-03-05 Stemcentrx, Inc. Novel sez6 modulators and methods of use
KR102522346B1 (ko) 2013-08-29 2023-04-17 시티 오브 호프 세포침투 콘주게이트 및 이의 사용 방법
DK3049441T3 (da) 2013-09-27 2020-02-03 Hoffmann La Roche Anti-PDL1-antistofformuleringer
AP2016009222A0 (en) 2013-11-04 2016-05-31 Glenmark Pharmaceuticals Sa Production of t cell retargeting hetero-dimeric immunoglobulins
CN105814081B (zh) 2013-11-13 2021-02-02 辉瑞大药厂 肿瘤坏死因子样配体1a特异性抗体及其组合物和用途
EP3077412B1 (en) 2013-12-02 2023-01-04 Baylor College of Medicine Identification of a new polypeptide hormone for maintenance of optimal body weight and blood glucose
WO2015087187A1 (en) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anti-sclerostin antibodies
US20150210772A1 (en) 2013-12-17 2015-07-30 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
MX2016007965A (es) 2013-12-17 2016-10-28 Genentech Inc Terapia de combinacion que comprende agonistas de union a ox40 y antagonistas de union al eje pd-1.
ES2763429T5 (es) 2013-12-17 2023-06-21 Hoffmann La Roche Procedimientos de tratamiento de cánceres usando antagonistas de la unión al eje de PD-1 y taxanos
US10273301B2 (en) 2013-12-24 2019-04-30 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
WO2016114819A1 (en) 2015-01-16 2016-07-21 Academia Sinica Compositions and methods for treatment and detection of cancers
KR20160104727A (ko) 2014-01-16 2016-09-05 아카데미아 시니카 암의 치료 및 검출을 위한 조성물 및 방법
WO2015109212A1 (en) 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
US20170044232A1 (en) 2014-02-04 2017-02-16 Genentech, Inc. Mutant smoothened and methods of using the same
EP3119804A2 (en) 2014-03-19 2017-01-25 Dana-Farber Cancer Institute, Inc. Immunogenetic restriction on elicitation of antibodies
MX378344B (es) 2014-03-21 2025-03-10 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos.
JP7054990B2 (ja) 2014-03-27 2022-04-15 ジェネンテック， インコーポレイテッド 炎症性腸疾患の診断及び治療のための方法
ES2811274T3 (es) 2014-04-18 2021-03-11 Univ Leland Stanford Junior Anticuerpos monoclonales humanizados y quiméricos para CD99
EP3613433B1 (en) 2014-05-30 2022-01-05 Shanghai Henlius Biotech, Inc. Anti-epidermal growth factor receptor (egfr) antibodies
ES2779412T3 (es) 2014-06-17 2020-08-17 Medimmune Ltd Anticuerpos Alfa-V Beta-8 mejorados
TWI695011B (zh) 2014-06-18 2020-06-01 美商梅爾莎納醫療公司 抗ｈｅｒ２表位之單株抗體及其使用之方法
RU2017115315A (ru) 2014-10-03 2018-11-08 Дана-Фарбер Кэнсер Инститьют, Инк. Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения
CA2962949C (en) 2014-10-06 2024-03-05 Dana-Farber Cancer Institute, Inc. Humanized cc chemokine receptor 4 (ccr4) antibodies and methods of use thereof
CN108064308B (zh) 2014-11-05 2023-06-09 豪夫迈·罗氏有限公司 细菌中产生双链蛋白的方法
RU2739500C2 (ru) 2014-11-05 2020-12-25 Дженентек, Инк. Способы получения двуцепочечных белков в бактериях
CN106999583A (zh) 2014-11-17 2017-08-01 豪夫迈·罗氏有限公司 包含ox40结合激动剂和pd‑1轴结合拮抗剂的组合疗法
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
WO2016115275A1 (en) 2015-01-13 2016-07-21 City Of Hope Ctla4-binding protein peptide-linker masks
AU2016206475B2 (en) 2015-01-16 2021-11-04 City Of Hope Cell penetrating antibodies
TWI710571B (zh) 2015-01-24 2020-11-21 中央研究院 腫瘤標記及其使用方法
CN107636170A (zh) 2015-02-04 2018-01-26 健泰科生物技术公司 突变型Smoothened及其使用方法
EP3978530A1 (en) 2015-02-26 2022-04-06 F. Hoffmann-La Roche AG Integrin beta7 antagonists and methods of treating crohn's disease
CA2981504C (en) 2015-03-30 2023-10-24 City Of Hope Mechanically interlocking complexes
CN114456272A (zh) 2015-04-03 2022-05-10 优瑞科生物技术公司 靶向afp肽/mhc复合体的构建体及其用途
US11135282B2 (en) 2015-04-08 2021-10-05 Dana-Farber Cancer Institute, Inc. Humanized influenza monoclonal antibodies and methods of use thereof
HUE057285T2 (hu) 2015-04-13 2022-04-28 Pfizer Terápiás ellenanyagok és alkalmazásaik
EP3288977B1 (en) 2015-05-01 2021-11-17 Dana-Farber Cancer Institute, Inc. Methods of mediating cytokine expression with anti ccr4 antibodies
CN107849102B (zh) 2015-05-15 2022-05-13 希望之城 嵌合抗原受体组合物
DK3447075T3 (da) 2015-05-15 2023-11-13 Massachusetts Gen Hospital Antagonistiske antistoffer af antitumornekrosefaktorreceptor-superfamilien
MX388405B (es) 2015-05-29 2025-03-19 Genentech Inc Un anticuerpo anti-pd-l1 para usarse en el tratamiento de cáncer en sujetos que tienen nivel medio o bajo de metilación en la región promotora pd-l1.
HK1249016A1 (zh) 2015-06-02 2018-10-26 豪夫迈‧罗氏有限公司 使用抗il-34抗体治疗神经疾病的组合物和方法
HRP20260689T1 (hr) 2015-06-17 2026-07-17 F. Hoffmann-La Roche Ag Postupci za liječenje lokalno uznapredovalog ili metastatskog raka dojke primjenom antagonista vezivanja osi pd-1 i taksana
EP3722314A1 (en) 2015-06-24 2020-10-14 Janssen Pharmaceutica NV Anti-vista antibodies and fragments
US11066481B2 (en) 2015-07-23 2021-07-20 The Regents Of The University Of California Antibodies to coagulation factor XIa and uses thereof
EP3331543A4 (en) 2015-08-06 2019-03-20 City of Hope Cell-pollenizing protein antibody conjugates and methods of use
CA2997179A1 (en) 2015-09-02 2017-03-09 The Regents Of The Unversity Of Colorado, A Body Corporate Compositions and methods for modulating t-cell mediated immune response
JP2018529747A (ja) 2015-10-06 2018-10-11 ジェネンテック， インコーポレイテッド 多発性硬化症を治療するための方法
EP3365369A1 (en) 2015-10-23 2018-08-29 Pfizer Inc Anti-il-2 antibodies and compositions and uses thereof
CN108603037B (zh) 2015-12-10 2020-11-17 希望之城 细胞穿透花青偶联抗体
AU2016379425B2 (en) 2015-12-24 2021-11-11 Corvus Pharmaceuticals, Inc. Methods of treating cancer
SG10202103844WA (en) 2015-12-30 2021-06-29 Genentech Inc Use of tryptophan derivatives for protein formulations
US10525137B2 (en) 2015-12-30 2020-01-07 Genentech, Inc. Formulations with reduced degradation of polysorbate
BR112018011029A2 (pt) 2016-01-08 2018-11-21 Hoffmann La Roche métodos para tratar ou atrasar a progressão do câncer e para melhorar a função imune em um indivíduo com câncer, usos de um antagonista de ligação e de um anticorpo biespecífico, composições e kits
ES2904593T3 (es) 2016-01-21 2022-04-05 Pfizer Anticuerpos monoespecíficos y biespecíficos para la variante III del receptor del factor de crecimiento epidérmico y CD3 y sus usos
EP3408671B1 (en) 2016-01-25 2023-11-01 F. Hoffmann-La Roche AG Methods for assaying t-cell dependent bispecific antibodies
AU2017213826A1 (en) 2016-02-04 2018-08-23 Curis, Inc. Mutant smoothened and methods of using the same
US10899836B2 (en) 2016-02-12 2021-01-26 Janssen Pharmaceutica Nv Method of identifying anti-VISTA antibodies
WO2017157305A1 (en) 2016-03-15 2017-09-21 Generon (Shanghai) Corporation Ltd. Multispecific fab fusion proteins and use thereof
EP3436477A2 (en) 2016-03-29 2019-02-06 Janssen Biotech, Inc. Method of treating psoriasis with increased interval dosing of anti-il12 and/or -23 antibody
US10836720B2 (en) 2016-04-01 2020-11-17 The Regents Of The University Of California Inhibitors of integrin alpha 5 beta 1 and methods of use
WO2017175058A1 (en) 2016-04-07 2017-10-12 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
BR112018073133A2 (pt) 2016-05-10 2019-04-30 Genentech Inc métodos de diminuição das ligações trissulfeto durante a produção recombinante de polipeptídeos
CA3026518A1 (en) 2016-06-17 2017-12-21 Genentech, Inc. Purification of multispecific antibodies
KR20230047507A (ko) 2016-06-27 2023-04-07 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 암 치료 조합
CA3031194A1 (en) 2016-07-22 2018-01-25 Dana-Farber Cancer Institute, Inc. Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof
CN106079858B (zh) * 2016-08-03 2017-05-17 钟晴晴 一种丝网印刷机
EP3494139B1 (en) 2016-08-05 2022-01-12 F. Hoffmann-La Roche AG Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
WO2018029124A1 (en) 2016-08-08 2018-02-15 F. Hoffmann-La Roche Ag Therapeutic and diagnostic methods for cancer
CN115598231B (zh) 2016-08-15 2025-11-18 豪夫迈·罗氏有限公司 定量包含非离子表面活性剂和多肽的组合物中非离子表面活性剂的层析方法
CA3035081A1 (en) 2016-09-02 2018-03-08 Dana-Farber Cancer Institute, Inc. Composition and methods of treating b cell disorders
EP3509633A1 (en) 2016-09-06 2019-07-17 Dana-Farber Cancer Institute, Inc. Methods of treating or preventing zika virus infection
TW201825511A (zh) 2016-09-09 2018-07-16 美商艾斯合顧問有限公司 表現免疫檢查點調節子的溶瘤病毒
SI4339615T1 (sl) 2016-09-16 2026-01-30 Shanghai Henlius Biotech, Inc. Protitelesa anti-pd-1 za uporabo pri zdravljenju raka
SMT202600087T1 (it) 2016-09-23 2026-03-09 Teva Pharmaceuticals Int Gmbh Trattamento dell’emicrania refrattaria
EP3515488A1 (en) 2016-09-23 2019-07-31 Teva Pharmaceuticals International GmbH Treating cluster headache
EP3515494B1 (en) 2016-09-26 2026-02-25 The Brigham and Women's Hospital, Inc. Regulators of b cell-mediated immunosuppression
CN109862913B (zh) 2016-09-29 2023-09-05 加利福尼亚大学董事会 用于免疫疗法的αvβ8整联蛋白复合物的中和抗体
EP3519049B1 (en) 2016-09-30 2025-12-03 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-il23 specific antibody
CA3040812A1 (en) 2016-11-04 2018-05-11 Novimmune Sa Anti-cd19 antibodies and methods of use thereof
WO2018089967A1 (en) 2016-11-14 2018-05-17 Virginia Commonwealth University Inhibitors of cancer invasion, attachment, and/or metastasis
JP7645607B2 (ja) 2016-11-16 2025-03-14 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体で乾癬を治療する方法
TW201825515A (zh) 2017-01-04 2018-07-16 美商伊繆諾金公司 Ｍｅｔ抗體以及其免疫結合物及用途
EP3565845A4 (en) 2017-01-06 2020-10-07 Biosion, Inc. ERBB2 ANTIBODIES AND THEIR USES
CN110234351A (zh) 2017-01-30 2019-09-13 詹森生物科技公司 用于治疗活动性银屑病关节炎的抗tnf抗体、组合物和方法
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
US11198735B2 (en) 2017-03-03 2021-12-14 Rinat Neuroscience Corp. Anti-GITR antibodies and methods of use thereof
US11726091B2 (en) 2017-04-03 2023-08-15 The Regents Of The University Of California Compositions and methods of diagnosing pancreatic cancer
EP3609915A1 (en) 2017-04-12 2020-02-19 Pfizer Inc Antibodies having conditional affinity and methods of use thereof
RU2665790C1 (ru) 2017-04-17 2018-09-04 Закрытое Акционерное Общество "Биокад" Моноклональное антитело к pd-l1
EP4230649A3 (en) 2017-04-25 2023-10-25 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
EP3615574B1 (en) 2017-04-26 2026-06-24 Eureka Therapeutics, Inc. Constructs specifically recognizing glypican 3 and uses thereof
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
US11260117B2 (en) 2017-05-26 2022-03-01 Novimmune Sa Anti-CD47 x anti-mesothelin antibodies and methods of use thereof
JP7234142B2 (ja) 2017-06-02 2023-03-07 ファイザー・インク Ｆｌｔ３に特異的な抗体およびその使用
US11827669B2 (en) 2017-07-19 2023-11-28 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection
WO2019067015A1 (en) 2017-09-29 2019-04-04 City Of Hope RECEPTORS OF CHIMERIC ANTIGENS AND BISPECIFIC ANTIBODIES FOR THE TREATMENT OF COAT CELL LYMPHOMA
RU2698048C2 (ru) 2017-10-03 2019-08-21 Закрытое Акционерное Общество "Биокад" МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
MX2020004716A (es) 2017-11-06 2020-11-06 Janssen Biotech Inc Método seguro y eficaz para tratar la artritis psoriásica con el anticuerpo específico anti-il23.
CA3087331A1 (en) 2017-12-29 2019-07-04 City Of Hope Meditope-enabled t cells
MX2020008183A (es) 2018-02-01 2020-09-22 Pfizer Anticuerpos especificos para cd70 y sus usos.
JP7516250B2 (ja) 2018-03-05 2024-07-16 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ－２３特異的抗体を用いたクローン病の治療方法
AU2019234836A1 (en) 2018-03-13 2020-09-17 The Regents Of The University Of California Inhibitors of integrin alpha 2 beta 1 and methods of use
CN120399075A (zh) 2018-03-14 2025-08-01 诺维莫尼公司 抗-CD3ε抗体及其应用方法
CN108357203A (zh) * 2018-04-23 2018-08-03 广州市威顿彩印有限公司 一种彩印产线用转叶式干燥设备及其使用方法
EP3788071A1 (en) 2018-05-02 2021-03-10 The United States Of America, As Represented By The Secretary, Department of Health and Human Services Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
JP2021523138A (ja) 2018-05-11 2021-09-02 ヤンセン バイオテツク，インコーポレーテツド Ｉｌ−２３抗体を使用してうつを治療する方法
US11525010B2 (en) 2018-05-23 2022-12-13 Pfizer Inc. Antibodies specific for GUCY2c and uses thereof
WO2019224385A2 (en) 2018-05-24 2019-11-28 Glenmark Pharmaceuticals S.A. Combined bispecific antibody and immuno-oncology therapies
TW202017567A (zh) 2018-06-21 2020-05-16 美商優曼尼蒂治療股份有限公司 用於治療及預防神經病症之組成物及方法
TWI890148B (zh) 2018-06-23 2025-07-11 美商建南德克公司 以pd-1軸結合拮抗劑、鉑劑及拓撲異構酶ii抑制劑治療肺癌之方法
ES3061216T3 (en) 2018-06-29 2026-03-31 Hope City Cd6 targeted chimeric antigen receptors for treatment of certain autoimmune disorders
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
EP3823611A1 (en) 2018-07-18 2021-05-26 Genentech, Inc. Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent
WO2020016838A2 (en) 2018-07-18 2020-01-23 Janssen Biotech, Inc. Sustained response predictors after treatment with anti-il23 specific antibody
IL280525B2 (en) 2018-08-08 2024-11-01 Genentech Inc Use of tryptophan derivatives and l-methionine for protein formulation
WO2020041758A1 (en) 2018-08-24 2020-02-27 City Of Hope Masked cytokine conjugates
JP2022501388A (ja) 2018-09-19 2022-01-06 ラホヤ インスティチュート フォー イミュノロジー 関節リウマチにおけるｐｔｐｒｓ及びプロテオグリカン
AU2019342133B8 (en) 2018-09-21 2025-08-07 Genentech, Inc. Diagnostic methods for triple-negative breast cancer
CN113260626B (zh) 2018-11-05 2024-09-13 豪夫迈·罗氏有限公司 在原核宿主细胞中产生双链蛋白质的方法
MA55149A (fr) 2018-11-20 2021-09-29 Janssen Biotech Inc Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique anti-il-23
JPWO2020213724A1 (enExample) 2019-04-19 2020-10-22
EP3972690A4 (en) 2019-05-23 2023-07-05 Janssen Biotech, Inc. METHOD OF TREATMENT OF INFLAMMATORY BOWEL DISEASE USING COMBINATION THERAPY OF ANTIBODIES TO IL-23 AND TNF-ALPHA
MA56026A (fr) 2019-06-03 2022-04-06 Janssen Biotech Inc Anticorps anti-tnf, compositions et méthodes pour le traitement de la spondylarthrite ankylosante active
US20200385453A1 (en) 2019-06-04 2020-12-10 Janssen Biotech, Inc. Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody
AR119264A1 (es) 2019-06-05 2021-12-09 Genentech Inc Método para reutilización de cromatografía
WO2021010326A1 (ja) 2019-07-12 2021-01-21 中外製薬株式会社 抗変異型ｆｇｆｒ３抗体およびその使用
US11634501B2 (en) 2019-07-19 2023-04-25 Oncoresponse, Inc. Immunomodulatory antibodies and methods of use thereof
EP4004037A1 (en) 2019-07-26 2022-06-01 Vanderbilt University Human monoclonal antibodies to enterovirus d68
CN114127121B (zh) 2019-08-12 2025-04-11 北京恩瑞尼生物科技股份有限公司 用于通过cd39表达细胞的adcc靶向促进和增强t细胞介导的免疫反应的方法和组合物
WO2021028752A1 (en) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anti-tfn antibodies for treating type i diabetes
US20230076643A1 (en) 2019-12-30 2023-03-09 City Of Hope Methods of making and using regulatory t cells and effector t cells having chimeric antigen receptors targeted to cd6, cd19, and/or an il-13r for treatment of autoimmune disorders and cancers
KR20220140568A (ko) 2020-02-11 2022-10-18 벤더르빌트 유니버시티 중증 급성 호흡기 증후군 코로나바이러스 2(SARS-CoV-2)에 대한 인간 단일클론 항체
WO2021195385A1 (en) 2020-03-26 2021-09-30 Vanderbilt University HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-GoV-2)
WO2021195418A1 (en) 2020-03-26 2021-09-30 Vanderbilt University Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
WO2021205325A1 (en) 2020-04-08 2021-10-14 Pfizer Inc. Anti-gucy2c antibodies and uses thereof
US11634477B2 (en) 2020-04-28 2023-04-25 The Rockefeller University Neutralizing anti-SARS-CoV-2 antibodies and methods of use thereof
CA3181949A1 (en) 2020-05-05 2021-11-11 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
CA3183927A1 (en) 2020-05-21 2021-11-25 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
WO2021257503A1 (en) 2020-06-16 2021-12-23 Genentech, Inc. Methods and compositions for treating triple-negative breast cancer
AU2021308574A1 (en) 2020-07-13 2023-03-09 Janssen Biotech, Inc. Safe and effective method of treating psoriatic arthritis with anti-IL23 specific antibody
MX2023000662A (es) 2020-07-17 2023-02-27 Pfizer Anticuerpos terapeuticos y sus usos.
MX2023004299A (es) 2020-10-13 2023-07-07 Univ Pennsylvania Direccionamiento de células t cd4+ in vivo para terapeuticos de arnm.
US11919945B2 (en) 2020-11-04 2024-03-05 The Rockefeller University Neutralizing anti-SARS-CoV-2 antibodies
EP4277926A1 (en) 2021-01-15 2023-11-22 The Rockefeller University Neutralizing anti-sars-cov-2 antibodies
MX2023008485A (es) 2021-01-20 2023-07-28 Oncoresponse Inc Anticuerpos inmunomoduladores y usos de estos.
BR112023018353A2 (pt) 2021-03-12 2024-02-06 Janssen Biotech Inc Método seguro e eficaz para tratamento da artrite psoriática com anticorpo específico anti-il23
EP4305062A1 (en) 2021-03-12 2024-01-17 Janssen Biotech, Inc. Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody
US12448444B2 (en) 2021-03-22 2025-10-21 Novimmune Sa Bispecific antibodies targeting CD47 and PD-L1 and methods of use thereof
JP2024512574A (ja) 2021-03-22 2024-03-19 ノビミューン エスアー Ｃｄ４７およびｐｄ－ｌ１を標的とする二重特異性抗体ならびにその使用方法
WO2022235867A2 (en) 2021-05-06 2022-11-10 The Rockefeller University Neutralizing anti-sars- cov-2 antibodies and methods of use thereof
CN118541392A (zh) 2021-09-28 2024-08-23 准星生物医药有限公司 多种形式的分子复合物
KR20240099352A (ko) 2021-10-29 2024-06-28 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체로 크론병을 치료하는 방법
IL312538A (en) 2021-11-05 2024-07-01 Abviro Llc Broadly reactive human monoclonal influenza antibodies and methods for their use
JP2024544555A (ja) 2021-11-15 2024-12-03 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体によるクローン病を処置する方法
KR20240103043A (ko) 2021-11-23 2024-07-03 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체로 궤양성 결장염을 치료하는 방법
EP4469159A1 (en) 2022-01-27 2024-12-04 The Rockefeller University Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
CN114485122A (zh) * 2022-02-24 2022-05-13 广西青松木业有限公司 一种隧道式木材单板烘干生产线
EP4493593A1 (en) 2022-03-18 2025-01-22 Evolveimmune Therapeutics, Inc. Bispecific antibody fusion molecules and methods of use thereof
JP2025512860A (ja) 2022-03-30 2025-04-22 ヤンセン バイオテツク，インコーポレーテツド Ｉｌ－２３に特異的な抗体によって軽度から中等度の乾癬を治療する方法
GB202204813D0 (en) 2022-04-01 2022-05-18 Bradcode Ltd Human monoclonal antibodies and methods of use thereof
EP4504148A1 (en) 2022-04-01 2025-02-12 Genentech, Inc. Hydroxypropyl methyl cellulose derivatives to stabilize polypeptides
CA3248580A1 (en) 2022-04-29 2023-11-02 Purinomia Biotech, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES AND DISORDERS CAUSED BY EOSINOPHIL ACTIVITY
WO2023215498A2 (en) 2022-05-05 2023-11-09 Modernatx, Inc. Compositions and methods for cd28 antagonism
EP4526342A1 (en) 2022-05-18 2025-03-26 Janssen Biotech, Inc. Method for evaluating and treating psoriatic arthritis with il23 antibody
AU2023362569A1 (en) 2022-10-21 2025-04-24 Novimmune Sa Pd-l1xcd28 bispecific antibodies for immune checkpoint-dependent t cell activation
WO2024097639A1 (en) 2022-10-31 2024-05-10 Modernatx, Inc. Hsa-binding antibodies and binding proteins and uses thereof
AU2023383916A1 (en) 2022-11-22 2025-07-10 Janssen Biotech, Inc. Method of treating ulcerative colitis with anti-il23 specific antibody
US20260191905A1 (en) 2022-12-01 2026-07-09 Modernatx, Inc. Gpc3-specific antibodies, binding domains, and related proteins and uses thereof
US20260234253A1 (en) 2023-02-14 2026-08-13 Evolvelmmune Therapeutics, Inc. Combination of bispecific antibodies and chimeric antigen receptor t cells for treatment
WO2024206126A1 (en) 2023-03-27 2024-10-03 Modernatx, Inc. Cd16-binding antibodies and uses thereof
EP4777539A1 (en) 2023-09-11 2026-07-22 Evolveimmune Therapeutics, Inc. Bispecific antibody fusion molecules targeting b7-h4 and cd3 and methods of use thereof
CN117190671B (zh) * 2023-09-13 2025-08-26 莱阳银通纸业有限公司 一种种子纸快速风干设备及方法
EP4780849A1 (en) 2023-09-20 2026-07-29 Evolveimmune Therapeutics, Inc. Multispecific antibodies that bind cd3 and cd2 and methods of use thereof
CN122094980A (zh) 2023-09-20 2026-05-26 进化免疫治疗公司 靶向cd180和cd3的双特异性抗体融合分子及其使用方法
US20250109187A1 (en) 2023-09-28 2025-04-03 Novavax, Inc. ANTI-SARS-CoV-2 SPIKE (S) ANTIBODIES AND THEIR USE IN TREATING COVID-19
IL328469A (en) 2023-11-28 2026-07-01 Novimmune Sa Method for treating disease using antibodies against CD47 and against mesothelin as a single agent and in combination with antibodies against PD-1
CA3249015A1 (en) 2024-03-20 2025-10-31 Janssen Biotech, Inc. Methods of treating crohn’s disease with anti-il23 specific antibody
WO2025262604A1 (en) 2024-06-17 2025-12-26 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
WO2026082966A1 (en) 2024-10-18 2026-04-23 Novimmune Sa Methods of treating disease using anti-cd47 x anti-mesothelin antibodies in combination with chemotherapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1543585A (en) * 1923-03-24 1925-06-23 Heekin Can Company Synchronized press and oven conveyer
GB793216A (en) * 1956-02-18 1958-04-09 James Arthur Black Improvements in or relating to a method of and machine or apparatus for drying coated sheet stock
DE1222083B (de) * 1962-04-02 1966-08-04 Rank Xerox Ltd Einrichtung zum Transportieren von Papier- od. dgl. Blaettern

Also Published As

Publication number Publication date
DE2860970D1 (en) 1981-11-12
FR2413974A1 (fr) 1979-08-03
EP0003089A1 (fr) 1979-07-25
EP0003089B1 (fr) 1981-08-12

Similar Documents

Publication Publication Date Title
FR2413132B1 (enExample)
FR2414552B1 (enExample)
FR2415429B1 (enExample)
FR2415739B1 (enExample)
FR2415100B1 (enExample)
FR2415219B1 (enExample)
FR2413224B1 (enExample)
FR2416953B1 (enExample)
FR2414971B3 (enExample)
FR2416748B1 (enExample)
AU3898778A (enExample)
FR2416079B1 (enExample)
AU3892778A (enExample)
DK168678A (enExample)
AU73950S (enExample)
BG26014A1 (enExample)
BG25843A1 (enExample)
BG25957A1 (enExample)
BG25858A1 (enExample)
BG25940A1 (enExample)
BG25874A1 (enExample)
BG26006A1 (enExample)
BG26009A1 (enExample)
BG26008A1 (enExample)
BE871570A (enExample)

Legal Events

Date Code Title Description
TP Transmission of property
CL Concession to grant licenses
ST Notification of lapse